Expert Advice on Managing Severe Asthma
  • CME

Source: Severe Eosinophilic Asthma: Key Decisions That Drive Effective Strategies with Targeted Therapies
LAUNCH TOOL
ACCEPT DISCLAIMER AND LAUNCH TOOL
Enter asthma patient characteristics in this online CCO tool and compare your treatment plan with those of 5 experts.
Michael E. Wechsler, MD, MMSc
Program Director
Bradley E. Chipps, MDFAAP, FACAAI, FAAAAI, FCCP
Nicola Alexander Hanania, MD, MS
Linda Rogers, MD
Eileen Wang, MD, MPH
Physicians: maximum of 0.25 AMA PRA Category 1 Credits™
Released: August 5, 2020 Expiration: August 4, 2021
Interactive Decision Support Tool
Managing Severe Asthma
LAUNCH TOOL
ACCEPT DISCLAIMER AND LAUNCH TOOL

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Select a biologic-based treatment strategy that targets the proinflammatory mechanisms of severe eosinophilic asthma
  • Describe the efficacy and safety of novel targeted biologic agents that have been recently approved as add-on therapy for severe eosinophilic asthma

Disclaimer

Disclaimer: Access to and use of this Interactive Decision Support Tool titled, “Expert Advice on Managing Severe Asthma,” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate clinicians on assessing and treating patients with uncontrolled asthma. The information provided is based on expert guidance of Bradley E. Chipps, MDFAAP, FACAAI, FAAAAI, FCCP; Nicola Alexander Hanania, MD, MS; Linda Rogers, MD; Eileen Wang, MD, MPH; and Michael E. Wechsler, MD, MMSc.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Expert Advice on Managing Severe Asthma” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.
© 2020 Clinical Care Options, LLC. All rights reserved.

This activity is supported by educational grants from
Novartis Pharmaceuticals Corporation
Sanofi Genzyme and Regeneron Pharmaceuticals

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Michael E. Wechsler, MD, MMSc

Professor of Medicine
Director, NJH Cohen Family Asthma Institute
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Hospital
Denver, Colorado

Michael E. Wechsler, MD, MMSc, has disclosed that he has received funds for research support from AstraZeneca, Regeneron, Sanofi Genzyme, and Teva and consulting fees from AstraZeneca, Cohero, Equillium, Genentech, GlaxoSmithKline, Novartis, Regeneron, resTORbio, Sanofi Genzyme, and Teva.

Faculty

Nicola Alexander Hanania, MD, MS

Associate Professor of Medicine
Department of Pulmonary and Critical Care Medicine
Baylor College of Medicine
Houston, Texas

Nicola Alexander Hanania, MD, MS, has disclosed that he has received funds for research support from AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Gossamer Bio, Novartis, and Sanofi Genzyme; consulting fees from Boehringer Ingelheim, GlaxoSmithKline, Mylan Novartis, and Sanofi Genzyme; and fees for non-CME/CE services from GlaxoSmithKline, Mylan, and Sanofi Genzyme.
Bradley E. Chipps, MDFAAP, FACAAI, FAAAAI, FCCP

President
Medical Director
Capital Allergy & Respiratory Disease Center
Sacramento, California

Bradley E. Chipps, MDFAAP, FACAAI, FAAAAI, FCCP, has disclosed that he has received consulting fees and fees for non-CME/CE services from AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Novartis, Regeneron, and Sanofi Genzyme.
Eileen Wang, MD, MPH

Assistant Professor
Division of Allergy and Immunology
Department of Medicine
National Jewish Health
University of Colorado School of Medicine
Denver and Aurora, Colorado

Eileen Wang, MD, MPH, has disclosed that she has received fees for non-CME/CE services from AstraZeneca and funds for research support from Genentech and GlaxoSmithKline.
Linda Rogers, MD

Associate Professor of Medicine
Mount Sinai National Jewish Health Respiratory Institute
Icahn School of Medicine at Mount Sinai
Clinical Director, Adult Asthma Program
Division of Pulmonary, Critical Care, and Sleep Medicine
Department of Medicine
Mount Sinai Health System
New York, New York

Linda Rogers, MD, has disclosed that she has received funds for research support from AstraZeneca and Sanofi; consulting fees from AstraZeneca, Novartis, and Sanofi; and other financial or material support from AstraZeneca.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSC, ELS, has no relevant conflicts of interest to report.
Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for allergists, immunologists, pulmonologists, primary care physicians, physician assistants, and other healthcare providers who care for patients with severe eosinophilic asthma.

Goal

The goal of this activity is to leverage a point-of-care tool along with expert commentary to improve the competence and performance of learners in diagnosing, assessing, and treating patients with severe eosinophilic asthma.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 05, 2020, through August 04, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Concise CCO expert commentary on assessment and treatment choice for patients not controlled on traditional asthma therapies

Michael E. Wechsler, MD, MMSc Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: August 24, 2020 Expired: August 23, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue